Given the focus on sustained release and extended duration anti-VEGF assets due to the burden in AMD and DR patients caused by frequent IVT injections and trips to the clinic, large eye models of long-term vascular instability and exudation, such as the dl-AAA rabbit model, will be helpful in predicting clinical duration of action. This evidence concerns the gene VEGFA and age-related macular degeneration.